Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aerie Pharmaceuticals (NQ: AERI )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aerie Pharmaceuticals

< Previous 1 2 Next >
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
From Alcon Inc. Investors
Via Business Wire
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Aerie Pharmaceuticals, Inc.
Via Business Wire
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
From Kahn Swick & Foti, LLC
Via Business Wire
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
From Aerie Pharmaceuticals, Inc.
Via Business Wire
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
From Kahn Swick & Foti, LLC
Via Business Wire
AERI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Aerie Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) is engaged within the research, development and commercialization of ophthalmic therapies for the treatment of 
Via Spotlight Growth
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
From Alcon Inc. Investors
Via Business Wire
Aerie Pharmaceuticals Announces New Employee Inducement Grant
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces New Employee Inducement Grant
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)
From Aerie Pharmaceuticals
Via Business Wire
Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.